Adjusted mean±se response in peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) at week 24, following once-daily tiotropium Respimat.

Slides:

Advertisements

Similar presentations

내과 R2 이지훈 N Engl J Med Sep 8.

Advertisements

The Advanced Role of Tiotropium in

Once-daily tiotropium add-on to at least ICS improves control and reduces exacerbation risk in symptomatic asthma, independent of serum IgE or blood.

The Role of the Primary Care Physician in Helping Adolescent and Adult Patients Improve Asthma Control Barbara P. Yawn, MD, MSc Mayo Clinic Proceedings

The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD

Asthma diagnosis and treatment: Filling in the information gaps

The Modern Management of Asthma: Getting it right Part 2

A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma Stanley J. Szefler, MD, Kevin Murphy,

Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma Christian Vogelberg, MD, PhD, Michael Engel, MD, István.

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial Pierluigi Paggiaro,

Summary findings regarding the efficacy/safety profile across xanthines in chronic obstructive pulmonary disease patients. a) Combined plot of the change.

The values for the provoking dose of mannitol to cause a 15% decrease (PD15) in forced expiratory volume in 1 s (FEV1) showing the different levels of.

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

A) Peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) response following once-daily tiotropium Respimat add-on to medium-dose.

Changes of a) spirometric, plethysmographic, and b) impedance data at 5 Hz induced by bronchodilator in flow limited (□) and nonflow limited (▓) patients.

Risk of bias summary for Cochrane review comparing pMDI and spacer to nebulisers to deliver β2-agonists to adults and children with acute asthma. Risk.

Forest plot showing the number of adults (at the top) and children (lower down) who were admitted to hospital after treatment in the emergency department.

Treatment algorithm for managing chronic thromboembolic pulmonary hypertension (CTEPH), from the European Society of Cardiology/European Respiratory Society.

Kaplan–Meier analysis of survival over 2 years of treatment with riociguat in the CHEST-2 study [54]. Kaplan–Meier analysis of survival over 2 years of.

Representative diaphragm electromyogram (EMG) tracings at rest (a and b) and during maximum voluntary ventilation (c and d) in a healthy subject (a and.

Roflumilast negli studi di Fase III: i dati di efficacia

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

A–f) Respiratory mechanical measurements during incremental cycle exercise in patients with moderate chronic obstructive pulmonary disease (COPD) and age-matched.

Probability of death as a function of the number of months after randomisation in the National Emphysema Treatment Trial comparing medical therapy (––––)

Pinja Ilmarinen, PhD, Leena E

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Schematic overview of the suggested pharmacological management of chronic obstructive pulmonary disease (COPD). Schematic overview of the suggested pharmacological.

Benefit–risk balance and its individual determinants with personalised chronic obstructive pulmonary disease (COPD) treatment choices. Benefit–risk balance.

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to previous chronic obstructive pulmonary.

A) Total Asthma Quality of Life Questionnaire (AQLQ) score over 12 months after treatment with bronchial thermoplasty (BT) in the per protocol population.

The projected numbers of tobacco-related deaths between 2000–2035 in millions for a) the world and b) medium- and low-income countries (top) and high-income.

Post-bronchodilator forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio in subjects aged >50 yrs. Post-bronchodilator forced expiratory.

Forest plot meta-analysis of the impact of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations on changes in.

Kaplan–Meier curves for the probability of a first adjudicated primary end-point event in the AMBITION trial, suggesting that the primary outcome events.

Comparison between prediction equations from Wang et al

Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational.

Change in physiological variables from baseline values a) at rest and b) during exercise after saline infusion and exposition to different β-blocker agents.

The Journal of Allergy and Clinical Immunology: In Practice

Exposure to intermittent hypoxia after 13 nights led to an increase in sympathetic activity measured by muscle sympathetic nerve activity (MSNA). Exposure.

Typical example of posterior–anterior scans of the lungs after inhaling Technegas on day 1 (control; a) and after increasing doses of methacholine (b–d).

The effect of inhaled tiotropium (18 μg once daily) on the improvement in treadmill exercise endurance time in patients with chronic obstructive pulmonary.

Impact of dose adjustment in case of adverse drug reaction (ADR; includes dose interruption and/or reduction). a) No dose adjustment and b) dose adjustment.

Eckard Hamelmann, MD, Eric D

Overall forest plot from meta-analysis carried out in 11 studies a) assessing the relative risk of adverse events; and subgroup analysis performed on studies.

Relationship between a) forced expiratory flow at 25–75% of forced vital capacity (FVC) (FEF25–75%) and b) forced expiratory flow at 75% of FVC (FEF75%)

Cumulative mortality over 60 months in patients with α1-antitrypsin deficiency and an initial forced expiratory volume in 1 s

Cardiac index (CI) changes from baseline following single oral doses of riociguat (○) 1 mg and 2.5 mg compared with inhaled nitric oxide (•) in patients.

A) Tidal volume (VT) (presented as % predicted of vital capacity (VC)), b) breathing frequency (Fb), c) dynamic inspiratory capacity (IC) and d) inspiratory.

Effect of omalizumab (n = 209) on a) clinically significant and b) severe exacerbation rates, compared with placebo (n = 210). #: adjustment due to a pre-study.

Forest plot from meta-analysis carried out on four studies including high-dose N-acetylcysteine (NAC) treatment a) assessing the relative risk of chronic.

Lung function adjusted for body length and gestational age in male and female premature infants. Lung function adjusted for body length and gestational.

Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.

Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification based on symptom and risk evaluation. a) GOLD model of symptom/risk evaluation.

The European population from 1950 to 2050, with estimated population before 2006 (light background) and projected population (dark background). The European.

Risk ratio (RR) and number needed to treat (NNT) are time-dependent measures. a) When an intervention is associated with constant relative risk reduction.

Single photon emission computed tomography ventilation images of a female asthmatic at a, b) baseline and c, d) post-methacholine challenge, at approximately.

Reduction in mean pulmonary vascular resistance (PVR) in 37 subjects following acute sildenafil administration to ongoing bosentan therapy in the COMPASS-1.

A) Operating lung volumes and b) breathing frequency (Fb) during incremental cycle exercise in patients with moderate chronic obstructive pulmonary disease.

24-h blood pressure profile after a, d) one night of intermittent hypoxia (IH) exposure, b, e) 13 nights IH exposure and c, f) 5 days after cessation of.

Study designs for double-blind single maintenance and reliever therapy (SMART) studies. Study designs for double-blind single maintenance and reliever.

Interventional bronchoscopic and surgical treatments for chronic obstructive pulmonary disease (COPD). Interventional bronchoscopic and surgical treatments.

Mean change from baseline in percentage predicted forced vital capacity (FVC) in the a) phase III CAPACITY [27] and b) ASCEND [14] studies. #: n=174; ¶:

Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.

Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of.

Flow–volume loops of test breaths and preceding control breaths of three representative chronic obstructive pulmonary disease patients with different degrees.

Correlation between leg fluid volume (LFV) displacement measured by electrical impedance and apnoea/hypopnoea index (AHI) in non-obese obstructive sleep.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (Rio) compared with inhaled nitric oxide (NO) in patients with chronic.

Tracing of tidal breathing followed by an inspiratory manoeuvre to total lung capacity (TLC) to record inspiratory capacity (IC), followed by a full expiration.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Interrelationships are shown between exertional dyspnoea intensity and a) minute ventilation (V′E) and b) the tidal volume (VT)/inspiratory capacity (IC)

Presentation transcript:

Adjusted mean±se response in peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) at week 24, following once-daily tiotropium Respimat add-on to high-dose inhaled corticosteroids (ICS) plus a long-acting β2-agonist (LABA) in adults wi... Adjusted mean±se response in peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) at week 24, following once-daily tiotropium Respimat add-on to high-dose inhaled corticosteroids (ICS) plus a long-acting β2-agonist (LABA) in adults with severe symptomatic asthma, in a) NCT00772538 and b) NCT00776984. Adjusted for treatment, centre, visit, baseline, treatment-by-visit interaction and baseline-by-visit interaction. Full analysis set. c) Cumulative number of severe exacerbations, over 48 weeks, following once-daily tiotropium Respimat add-on to high-dose ICS plus a LABA in adults with severe symptomatic asthma. Pooled data (NCT00772538 and NCT00776984). Risk reduction of 21% (hazard ratio 0.79, p=0.03). Full analysis set. *: p<0.05; **: p<0.01; ***: p<0.001. Reproduced and modified from [58] with permission from the publisher. William W. Busse et al. Eur Respir Rev 2016;25:54-64 ©2016 by European Respiratory Society